Objective: Up to 15% of depression patients eventually present with treatment-resistant or refractory depression (TRD), a condition that causes significant social and economic burdens. Our paper aims to summarize the current medical literature on the conceptual and methodologic issues involved in the definition, assessment, and staging of TRD.
A lthough the therapeutic armamentarium available for clinicians treating MDD patients has expanded substantially over the last decades, TRD in its broadest sense still characterizes a significant number of patients in therapy. 1, 2 About one-third of patients treated for major depression do not respond satisfactorily to the first antidepressant prescribed. 3, 4 There are many individuals (up to 15% of patients) for whom multiple interventions will be unhelpful and who will have significant depression despite aggressive pharmacologic and psychotherapeutic approaches. [1] [2] [3] Although TRD appears to be relatively common in clinical practice, the inconsistent way in which it has been characterized and defined has been a major problem and has limited systematic research. 2 There are no definitive consensual standardized operational criteria for TRD, and one can find more than 10 disparate definitions while searching the specialized literature. 1, 4 This confused context may explain, at least in part, why assisting treatment-resistant or treatment-refractory depression patients still remains a daunting task even when one applies the currently available evidence-based systematic algorithms.
This paper aims to summarize the current conceptual and methodologic issues regarding the definition, assessment, and staging of TRD in adult patients.
Literature Search and Review
We performed a systematic review of the recent literature to identify papers specifically discussing TRD. The selection process involved 3 steps. First, we searched the MEDLINE, PsycINFO, and EMBASE databases for potentially relevant English-language articles published between January 1996 and June 2006. For the search, we used a combination of the following title words: resistant, refractor*, difficult, intractable, antidepress*,"and depress*. Second, we retrieved relevant articles (judged on the basis of the title and abstract) for more detailed evaluation. Articles were included if they focused on conceptual and methodologic aspects of treatment-resistant or treatment-refractory unipolar major depression, if they were published in peer-reviewed journals, and if they were written in English. Third, we hand-searched the bibliographies of relevant articles and of mood disorder textbooks for additional references. In total, we retrieved 327 full electronic references, 16 of which met our selection criteria. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 
Defining Resistance to Treatment in Unipolar Depression

Central Issues
Although various definitions have been suggested and loosely used in the literature, TRD is broadly defined as the occurrence of an insufficient clinical response following adequate antidepressant therapy (in terms of dosage, duration, and compliance) among patients diagnosed with major depression. 6, 15, 16 However, the required number of adequately delivered trials and when these trials should be considered indicative of treatment resistance (that is, in the current episode only or in previous episodes also) remains debatable. 8, 17 During the last decades, several authors developed different criteria for considering the categorical presence of TRD, including a failure to respond to adequate dosages of a single TCA (for example, amytriptilyne), an MAOI (for example, phenelzine) trial for a minimum of 4 weeks, a single adequate antidepressant treatment, 3 or more adequate trials of treatment (one of which must have been a TCA), 5 or more adequate treatments, at least one trial of electroconvulsive therapy, or a single trial of the newer heterocyclic antidepressants. 1, 2, 5, 6, 8, 10 Unfortunately, none of these classifications have been systematically examined, verified for reliability, or validated for prospective predictive utility, and therefore, it is currently difficult to select criteria from among these different approaches to defining TRD. 10 Nevertheless, there is a general sense that a patient has clinically significant treatment resistance if a current episode of depression has not benefited from at least 2 adequate trials of different classes of antidepressants. 7, 14, 17, 18 There are, however, at least 2 methodologic issues related to this definition: first, it assumes that nonresponse to 2 agents of different classes is more difficult to treat than nonresponse to 2 agents of the same class; second, it postulates that a switch within one class is less effective than switch to a different class. 16 It is significant that neither supposition has been entirely supported by current the literature (for more detailed discussion, see Fava 16 ). Despite these limitations, this definition of the categorical presence of TRD is the one that is currently most accepted .
Regardless of the specific criteria, narrow definitions of TRD result in the selection of homogenous groups of absolute nonresponders that are suitable for biological investigations and research on clinical characteristics and predictive 10 In contrast, broader definitions of resistance apply more appropriately to the clinical reality of daily practice and allow consideration of a range of resistance severity. 2
Related Issues
The Spectrum of Treatment-Resistant Depression. There is variety among research groups as to whether TRD is a specific subtype of depression or whether it is a nebulous residual category. 19 However, there is an emerging consensus that TRD is usually best understood not as an all-or-none phenomenon but as one that occurs along a continuum ranging from partial response to complete treatment resistance. 2, 10, 11 Relative Compared With Absolute Resistance. Some authors have proposed that the definition of TRD should be divided into 2 categories: absolute and relative. 21 Absolute resistance to antidepressants was then defined as an inadequate response to a trial of medication given over an extended period of time (for example, 8 weeks) with a confirmed daily dosage compliance of the maximum nontoxic dosage. 8, 10 This definition takes no account of the number of previous forms of treatment received and thus may be practical in a clinical context as patients are classified as nonresponders to a specific antidepressant therapy. 14 Relative resistance, on the other hand, was referred to as a failure to respond to a less than adequate (in terms of dosage and duration) antidepressant trial. 2, 6 However, the latter definition is spurious because a patient's depression should be considered resistant or refractory to treatment only when an adequate intervention has been administered.
Chronic, Refractory, and Difficult-to-Treat
Depressions. An important distinction should be made between the terms resistant, chronic, refractory, and difficult-to-treat depressions because they are often used synonymously to describe a failure to respond to an unspecified number of adequate trials involving one or more courses of specific antidepressant treatment. Such terminology often causes confusion and leads to the inclusion of a highly heterogeneous population within TRD samples. 5, 10 A chronic specifier implies a major depressive episode continuously sustained for at least 2 years during which therapy has not necessarily been tried. 2 Conversely, difficult-to-treat depression includes not only cases that inherently do not respond to optimally delivered treatments (that is, TRD) but also depression treated under circumstances precluding the optimal delivery of potentially effective approaches (such as the use of subtherapeutic dosages, noncompliance, or intolerable side effects 17 ). Thus difficult to treat depression may or may not actually include TRD. Finally, to some authors, the term refractory suggests a greater (although usually not clearly specified) degree of resistance. 10, 11 The distinction between resistant and refractory seems to be arbitrary because these are somewhat overlapping constructs. Semantically, refractory and resistant appear to be synonymous. 22 Therefore, in principle they could be used interchangeably, although it seems that the term resistant has been applied more frequently in the literature.
Symptom Threshold Required for Treatment-Resistant
Depression. Although there is no definitive consensus regarding the degree of symptom severity that should be required to qualify the presence of TRD, it has been argued that it is necessary for patients to present with sufficient baseline symptom severity to provide a metric to detect a treatment effect. 17 Overall severity need not be as high as is typically suggested for trials of antidepressant treatment because even mild-tomoderate depressions carry reduced daily function as well as a worse prognosis than that faced by remitted patients. Accordingly, it has been suggested that a score of at least 16 on the 17-item Hamilton Depression Rating Scale is sufficient confirmation of TRD. 17 Previous Psychotherapeutic Treatments. Because the utility of some psychotherapies (interpersonal, cognitive, and behavioural) for patients with resistant depression has been recently shown, one can argue that the prevailing view of what constitutes an adequate antidepressant therapy appears somewhat narrow and pharmacocentric. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Nevertheless, some authors (for example, Rush et al 17 ) have argued that it is not essential for trials of medication for TRD to require that psychotherapy be proven ineffective. If, on the other hand, the interest is focused on the next best treatment for patients not responding to psychotherapy, it would be appropriate for resistance to one or more prior trials of psychotherapy to be carefully documented.
Assessment of Contributors to Treatment-Refractory Depression
Several clinical, biological, and sociodemographic variables have been studied in relation to response and (or) resistance to antidepressant therapy. Nevertheless, this literature yields largely unreliable results, owing especially to methodologic variability and the heterogeneity of depression itself (for more detailed discussion, see Fava 16 ; Berman and collaborators 6 ; and Kornstein and Schneider 12 ).
Depression Subtypes
The recognition of depression subtypes (particularly melancholic, psychotic, atypical, and seasonal) is an important element in the evaluation and management of TRD because individuals with different subtypes of depression may respond in somewhat different ways to the available therapies. 14, 15 Additionally, resistance to treatment may also be related to misdiagnosis of a unipolar MDD in patients with declared or undeclared BD. Patients with BD present in the depressive phase 2 to 3 times more often than they do in the manic state 24 and it is estimated that BD I is undetected in 35% to 45% of patients. 25 It is important to evaluate patients with TRD specifically for a history of manic or hypomanic episodes to rule out bipolar spectrum disorders.
Psychiatric Comorbidity
Many studies have reported the association between the presence of comorbid psychiatric disorders (especially anxiety, alcohol or substance use, and personality disorders) and TRD. 2, 12, 15 These comorbid disorders are often missed or are suboptimally treated, and they can confound both the evaluation and the management of depression. 26 The implication for treatment is to address these conditions simultaneously, if possible, to avoid consolidating treatment resistance (for more information see 1, 2, 6, 13 ).
Sociodemographic Factors
There is little evidence to support the idea that female sex is a risk factor for TRD 15 , although recent evidence does suggest that women may be less responsive than men to TCAs and may respond preferentially to SSRIs or MAOIs. 12 Further, in terms of age at onset, both ends of the spectrum have been described as risk factors for TRD. 12
Clinical Factors
Some studies have shown that a positive family history of affective disorders is associated with early onset of depression and with chronicity, both of which have been linked to TRD. 5, 6 Moreover, chronic forms of depression have been associated with poorer outcome in some, but not all, studies 5, 12 and the delay in initiating treatments was found to be a main predictor of chronicity and nonresponse. 10 Regarding the intensity of depression, it seems that mild and markedly severe presentations may be more refractory to somatic treatments. 6, 12 Finally, recent life event stressors and early childhood loss do not seem to be associated with poor long-term or acute treatment outcome. 5, 6 Biological Markers Despite significant research, there has not been substantial conclusive evidence of the significance or validity of biological markers (for example, the dexamethasone suppression test, monoamine markers, and sleep characteristics) in predicting response to treatment of individuals suffering from depression. 2, 5, 6, 15 Comorbid Medical Illness Organic factors may contribute to affective illness in as many as 50% of patients. 1, 16 In a patient with a suspected TRD, it is crucial to rule out the presence of underlying medical disorders, especially from an endocrinologic origin (hypothyroidism 1, 2 ) . Other examples of medical conditions that may contribute to TRD include Cushing's syndrome, neurological disorders (both cortical and subcortical), pancreatic carcinoma, connective tissue disorders, vitamin deficiencies, and certain viral infections. 2, 6 Several types of medications, such as immunosuppressants, steroids and sedatives, may also precipitate or contribute to resistance. 3 A diagnosis of secondary depression is usually associated with a significant likelihood of chronicity, despite adequate treatments. 1, 4, 10 Aggressive antidepressant therapy may need to accompany adequate medical management. 6
Evaluating the Adequacy of Antidepressant Treatments
There is strong evidence that up to 60% of depression patients initially classified as suffering from TRD fall into the category of pseudo-TRD. 6, 16 Community-based surveys have revealed that less than 50% of patients actually receive either an adequate dosage or duration of antidepressants, 8, 14 and this figure does not account for the high noncompliance rate for taking medications as prescribed. 2, 10 This is especially problematic in light of recent studies showing a therapeutic decrement whereby patients who have not responded to one antidepressant have a 20% lower chance of responding to the next antidepressant. 11 One of the clinician's fundamental tasks is to review the adequacy of treatment to date. 12 In particular, an adequate trial of antidepressant treatment must occur at each level of treatment resistance. 14 An adequate therapy typically consists of one or more trials with antidepressants that have established efficacy in MDD and that are prescribed in at least standard dosages (that is, dosages that have shown efficacy in randomized trials) for a duration long enough to produce significant therapeutic effects. 12, [16] [17] [18] 
Adequacy in Terms of Dosage
Underdosing of antidepressants has historically been one of the main causes of nonresponse to treatment, 1, 14 and the recommended adequate dosages have increased from 150 mg daily to between 250 and 300 mg daily of imipramine or its equivalent. 2 The maximum tolerated dosage according to dosage recommendations should be used (although for some anitdepressants, such as fluoxetine, there is a less clear need to reach maximal dosages before considering nonresponse 4, 6 ) .
Given that there is an estimated thirtyfold range of drug metabolism among individuals taking such medications (resulting, for example, from differences in drug handling and factors such as age, sex, weight, and physical condition), it is not uncommon that at least some patients who fail to respond to treatment may do so as a result of less than optimal plasma drug concentrations. 4, 8 For instance, up to 50% of patients treated with moderate dosages of imipramine (200 mg to
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The Canadian Journal of Psychiatry, Vol 52, No 1, January 2007 W 49 levels. [6] [7] [8] [9] [10] [11] [12] [13] [14] It is also important to evaluate the concomitant use of metabolic inducers that may be associated with relative reductions in antidepressant blood levels 16 as well as to consider that some patients may be rapid or fast metabolizers. In such cases, dosage adjustments may produce a significant treatment improvement. 27 For some antidepressants (imipramine, desipramine, and nortriptyline) drug efficacy may be correlated with the presence of adequate antidepressant plasma levels. 27 The problem with some newer antidepressants (for instance, SSRIs) is that some studies to date have suggested that increasing the dosage of an SSRI may not increase the probability of response but may increase both side effects burden and treatment costs. 14 Nonresponse in the absence of any side effect is a useful guide to raising the possibility of less than adequate antidepressant blood levels, and its measurement may be indicated in these circumstances. 1, 6, 7 Finally, medication intolerance may be another important cause of underdosing because discontinuation rates owing to intolerable side effects range from about 10% to 25%. 6 In clinical practice, patients experiencing difficulty tolerating standard dosages of medication may often (and wrongly) be left on subtherapeutic dosages. Many of the side effects eventually abate, and if not, they may become better tolerated, especially after the onset of clinical improvement.
Adequacy in Terms of Duration
Pressures of the clinical setting commonly lead practitioners to change pharmacologic strategies too early. Shifting regimens and incorrectly drawing the conclusion that a given medication is ineffective may also be considered a cause of nonresponse and (or) pseudo-TRD. 1, 8 Most definitions of adequate treatment length are derived from the conventions of industry-sponsored drug trials. However, the optimal duration of antidepressant drug treatment necessary for TRD patients may be considerably longer than the 6-week duration used in these studies. It has been suggested that prolonged trials of treatment, lasting more than 10 weeks, may lead to a therapeutic response in certain resistant or refractory cases. 1, 6, 17 Further, in elderly patients with depression, 12 weeks or more may be necessary for a satisfactory clinical improvement. 4, 13 Finally, most TCAs and SSRIs have a half-life of 20 to 58 hours, which results in steady-state plasma concentrations being achieved on average only 5 to 12 days after beginning any given dosage. The exception is fluoxetine, which has an average half-life of about 150 hours. This may account for continued evolution of treatment over an extended period of time. 14 There is a current lack of compelling evidence to support the advantage of prolonged trials over 6 to 8 weeks, compared with other treatment strategies. 2, 14 Of interest, it has been shown that minimal response after 4 weeks of antidepressant use predicts poorer outcome at 8 weeks. 16 
Adequacy in Terms of Patient Compliance
Another important step toward the assessment of TRD concerns the level of treatment nonadherence 5 because it has been estimated that nonadherence may account for as many as 20% of cases considered resistant or refractory. 15 Many reasons for patient noncompliance have been suggested, including a breakdown in the patient-doctor relationship, inadequate psychoeducation, and intolerable side effects. 14 The actual prevalence of noncompliance may be underestimated and difficult to assess. 6 Thus a collateral history from past records or from the patient's companion may be useful to assist in the evaluation of adherence. 12 Few studies to date have adequately assessed adherence in depression patients, even though good compliance in and of itself is strongly associated with a positive response. 8, 15 Further work in this area is urgently needed.
Adequacy in Terms of Treatment Outcome
What constitutes inadequate response to treatment of depression has been the subject of considerable debate, but most experts would probably argue that it is the failure to achieve remission. 18, 28 The recently completed National Institute of Mental Health-sponsored study, Sequenced Treatment Alternatives to Relieve Depression, used this criterion to define antidepressant treatment success. 29 Given the protracted and disabling nature of some cases of TRD, one may argue that even a 30% to 40% reduction in baseline symptom severity would probably provide a clinically meaningful benefit. 7 Not achieving remission despite adequate treatment usually results in the presence of residual depressive symptoms (for example, insomnia, fatigue, psychic or somatic anxiety, and excessive reactivity to social stress) that have consistently been shown to be associated with poorer outcomes, increased risk of relapse, and impaired social functioning. 8, 12, 28, 30 Despite its being a worthwhile treatment goal, only 25% to 50% of patients in clinical trials achieve remission 30 ; thus, some authors have suggested that it would be more practical to use either lack of response or the persistence of clinically significant levels of depressive symptoms-rather than the lack of remission-of a previous trial to define resistance. 17
Instruments Used to Assess Adequacy of Previous Antidepressant Treatment(s)
The literature provides the clinician with 3 main instruments to assess treatment resistance in depression. While 2 of them are clinician-rated (the Antidepressant Treatment History Form 13 ; and the Harvard Antidepressant Treatment History 31 ), one is self-rated (the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire 16 ). Of these instruments, only the Antidepressant Treatment History Form has been empirically validated with prospective treatment outcome reports. [13] [14] [15] [16] 
Staging Treatment-Refractory Depression
The classification of TRD in stages has been recently proposed where increasing resistance is equated with an increased failure to respond to antidepressant strategies. 10, 16 The rationale behind this approach is the clinical impression that the greater the degree of treatment resistance, the lower the probability of response to any new treatment. 17 This perspective has yet to be empirically tested, and it is important to keep in mind that all classifications of TRD are not diagnoses per se. Moreover, any staging system based on administered treatments has the limitation of being dependent on the available therapeutic options as they evolve over time, rather than being based on the underlying neurobiology of TRD. 2, 8 Despite these limitations, staging systems do have merit and are promising approaches to guide treatment selection and ultimately help predict long-term illness course. 1, 11 Below we summarize the 3 existing staging models for TRD.
Thase and Rush Staging Method
Thase and Rush 32 first proposed a model of staging 5 levels of resistance. In this model, patients are staged according to the number and classes of antidepressants that have failed to produce a response, with staging moving from more common (TCAs and SSRIs) to less common (MAOIs or electroconvulsive therapy) treatments (see Table 1 ).
This approach could be a very useful tool in the classification of TRD, although its predictive value with respect to treatment outcome has not yet been systematically assessed. 14 
Additional limitations of the Thase and Rush Staging Method
include the fact that the degree of intensity of each trial in terms of dosing and (or) duration is not accounted for. Further, it assumes that nonresponse to 2 agents of different classes is more difficult to treat than nonresponse to 2 agents of the same class. It also indirectly assumes that switching antidepressants within the same class is less effective than switching to an antidepressants in a different class. Although this may be the case with TCAs, switching between SSRIs appears to be sometimes associated with a favourable clinical response. 16 There is also an implicit hierarchy of antidepressants, in which MAOIs are considered superior to TCAs and SSRIs, and TCAs are considered more effective than SSRIs. This hierarchy has not been supported by metaanalyses of antidepressant clinical trials. The Thase and Rush Staging Method does not consider the role of augmentation or combination strategies. 16
The European Staging Method
According to the European approach, TRD is defined as a failure to respond to 2 adequate trials of different antidepressants given in adequate dosages for a period of 6 to 8 weeks 10 (see Table 2 ). This is in contrast to the Thase and Rush Staging Method, which refers to resistance as the failure of at least one adequate trial. Thus, for the European Staging Method, after the first trial patients are classified as nonresponders to the antidepressants prescribed (TCA, SSRI, MAOI). Staging of TRD would then correspond to the number of the following failed adequate medication trials. Additionally, the European Staging Method proposed the existence of a condition called chronic resistant depression, which was defined as a resistant or refractory depressive episode lasting more than 1 year, despite adequate interventions.
With reference to the European criteria, one must consider the possibility that the duration of adequate trials and the distinction between TRD and chronic resistant depression were arbitrarily chosen.
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Massachusetts General Hospital Staging Method
Given the above-mentioned concerns about the Thase and Rush Staging Method, a group from the Massachusetts General Hospital proposed a slightly different approach (see Table 3 ) that considers both the number of failed trials and the intensity or optimization of each trial but that does not make assumptions regarding a hierarchy of antidepressant classes. This method generates a continuous variable reflecting the degree of resistance in depression. 16 While such a staging approach has merit for producing an apparently more sound classification, the reliability of data is still limited by the accuracy of patient recall and medical records. Further, the scores attributed to each different treatment approach appear somewhat arbitrary, and it is not clear, for example, why augmentation increases the overall resistance score by 0.5 points and electroconvulsive therapy by 3 points; that is, these crude values do not seem to be empirically validated, but rather, arbitrarily chosen.
Recently, Petersen and colleagues 20 
Conclusion
Despite the numerous options available for the treatment of depression, many patients do not achieve a satisfactory improvement with adequate dosages of antidepressants given for sufficient durations and are eventually classified as presenting with TRD. Generally, these patients are highly demanding for their families and often require major involvement of health care services.
Despite its significant impact, there is still some degree of controversy regarding a suitable and definitive description of TRD. Nonetheless, the key parameters that define TRD have been described and include the accurate diagnosis of the current major depressive episode and of the presence of other psychiatric or medical comorbidity, as well as the assessment of response to previous and current treatments (with special reference to their number and adequacy in terms of dosage, duration, and patient compliance).
In summary, future research on TRD should include prospective studies addressing, among other issues, the validity of the proposed criteria, the naturalistic course of resistance through the longer term, the impact of depression comorbid with other psychiatric disorders and (or) physical conditions, the existence of possible predictors of treatment outcome, and innovative management strategies. Undoubtedly, a better understanding of TRD and the many facets of its etiology, as well as the availability of new and effective therapies, will decrease the morbidity and mortality of TRD and minimize the confusion and therapeutic nihilism for both clinicians and patients. 
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